La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

Onconetix Gestion

Gestion contrôle des critères 0/4

Nous ne disposons actuellement pas d’informations suffisantes sur le PDG.

Informations clés

Ralph Schiess

Directeur général

n/a

Rémunération totale

Pourcentage du salaire du PDG	n/a
Durée du mandat du directeur général	less than a year
Propriété du PDG	n/a
Durée moyenne d'occupation des postes de direction	1.6yrs
Durée moyenne du mandat des membres du conseil d'administration	1.7yrs

Mises à jour récentes de la gestion

Recent updates

PDG

Ralph Schiess (45 yo)

less than a year

Titularisation

Dr. Ralph Schiess, Ph D., serves as Chief Science Officer at Onconetix, Inc. since December 15, 2023 and serves as its Interim Chief Executive Officer since January 12, 2024. He Co-founded ProteoMediX AG i...

Équipe de direction

Nom	Position	Titularisation	Compensation	Propriété
Ralph Schiess	Interim CEO & Chief Science Officer	less than a year	pas de données	pas de données
Karina Fedasz	Interim Chief Financial Officer	less than a year	pas de données	pas de données
Brian Price	Head of Technology Strategy	4yrs	US$126.48k	pas de données
Frank Jaeger	Senior VP of Marketing & Business Development	1.6yrs	pas de données	pas de données
Andrew Skibo	Global Head of Biologics Operations	3.3yrs	pas de données	pas de données
Theodore Yoho	Head of Business Development	3.3yrs	pas de données	pas de données
Ali Fattom	Head of Science & Discovery	2yrs	pas de données	pas de données
Jay Newmark	Chief Medical Officer	1.4yrs	pas de données	pas de données
Christian Bruhlmann	Chief Strategy Officer & GM of Europe	less than a year	pas de données	pas de données
Donald Very	Senior VP of Commercial Research & Development	no data	pas de données	pas de données

1.6yrs

Durée moyenne de l'emploi

49yo

Âge moyen

Gestion expérimentée: L'équipe de direction de J4T n'est pas considérée comme expérimentée (ancienneté moyenne 1.5 ans), ce qui suggère une nouvelle équipe.

Membres du conseil d'administration

Nom	Position	Titularisation	Compensation	Propriété
John Rice	Member of Scientific Advisory Board	no data	pas de données	pas de données
Thomas Meier	Director	less than a year	pas de données	pas de données
James Sapirstein	Non Executive Chairman & Lead Independent Director	2.6yrs	US$182.12k	pas de données
Ajit Singh	Independent Director	less than a year	pas de données	pas de données
Sunetra Gupta	Member of Scientific Advisory Board	no data	pas de données	pas de données
Simon Tarsh	Independent Director	2.1yrs	US$112.62k	pas de données
Timothy Ramdeen	Independent Non-Executive Director	1.7yrs	US$82.67k	pas de données

1.7yrs

Durée moyenne de l'emploi

62.5yo

Âge moyen

Conseil d'administration expérimenté: Les membres du conseil d'administration de J4T ne sont pas considérés comme expérimentés (ancienneté moyenne 1.6 ans), ce qui suggère un nouveau conseil d'administration.

Onconetix Gestion

Gestion contrôle des critères 0/4

Informations clés

Mises à jour récentes de la gestion

Onconetix, Inc., Annual General Meeting, Sep 05, 2024

High number of new and inexperienced directors

High number of new and inexperienced directors

Onconetix, Inc. Announces Appointment of Ajit Singh to its Board of Directors

Onconetix, Inc. Announces Chief Executive Officer Changes

Onconetix, Inc. Announces Resignation of Erin Henderson as Chief Business Officer

Recent updates

Onconetix Provides Non-Compliance Update

Onconetix, Inc. announced that it expects to receive $5 million in funding

Onconetix, Inc. announced delayed 10-Q filing

Onconetix, Inc., Annual General Meeting, Sep 05, 2024

Onconetix, Inc. announced delayed 10-Q filing

Onconetix Receives Deficiency Notice from the Nasdaq Regarding Listing Rule 5550(b)(1)

Onconetix, Inc. announced delayed annual 10-K filing

High number of new and inexperienced directors

High number of new and inexperienced directors

Onconetix, Inc. Announces Appointment of Ajit Singh to its Board of Directors

Onconetix, Inc. Announces Chief Executive Officer Changes

Onconetix, Inc. Announces Resignation of Erin Henderson as Chief Business Officer

Onconetix, Inc. Announces Executive Appointments

Onconetix, Inc.(NasdaqCM:ONCO) dropped from NASDAQ Composite Index

Blue Water Biotech, Inc. (NasdaqCM:BWV) acquired ProteoMediX AG.

Blue Water Biotech, Inc. announced delayed 10-Q filing

High number of new and inexperienced directors

Blue Water Biotech, Inc. Appoints Bruce Harmon as CFO

Blue Water Biotech Receives Non-Compliance Notice from Nasdaq

Blue Water Biotech, Inc. Announces Notification from Nasdaq Related to Delayed Quarterly Report on Form 10-Q

Blue Water Biotech, Inc. Announces Executive Changes

Blue Water Biotech, Inc. announced delayed 10-Q filing

High number of new and inexperienced directors

Blue Water Biotech Secures License from Ohio State Board of Pharmacy to Operate as Pharmaceutical Wholesaler for Its FDA Approved Products

Blue Water Biotech, Inc. Announces Preliminary Preclinical Data Supporting the Use of Its Norovirus Shell and Plusion Virus-Like Particle Platform to Develop Novel Monkeypox Vaccine Candidate

Blue Water Biotech, Inc. (NasdaqCM:BWV) agreed to acquire Six FDA Approved Drugs from WraSer LLC and Xspire Pharma, LLC.

New major risk - Financial position

High number of new and inexperienced directors

Blue Water Vaccines, Inc. Appoints Frank Jaeger as Senior Vice President of Marketing and Business Development

Blue Water Vaccines Appoints Timothy Ramdeen to Its Board of Directors

High number of new and inexperienced directors

Blue Water Vaccines, Inc. (NasdaqCM:BWV) announces an Equity Buyback for $5 million worth of its shares.

Blue Water Vaccines Announces Appointment of Vuk Jeremic, to Its Board of Directors

Blue Water Vaccines Announces Plans to Evaluate Efficacy of Streptococcus Pneumoniae Vaccine Candidate Against Pneumococcal Pneumonia At the World Vaccine Congress in Barcelona

CEO, President & Executive Chairman recently sold €2.7m worth of stock

Blue Water Vaccines, Inc. Announces Appointment of Simon Tarsh to Board of Directors

Blue Water Vaccines, Inc. Announces Exploration of Its Virus-Like Particle (VLP) Platform for Use in Monkeypox Vaccine Candidate

Blue Water Vaccines, Inc. announced that it has received $9.999998 million in funding

Blue Water Vaccines, Inc. announced that it expects to receive $9.999998 million in funding

Blue Water Vaccines, Inc., Annual General Meeting, Aug 22, 2022

High number of new and inexperienced directors

Blue Water Vaccines, Inc. Presents New Data Supporting Universal Influenza Vaccine Candidate at the World Vaccine Congress 2022 in Washington, DC

Blue Water Vaccines, Inc. announced that it has received $7.999411 million in funding

Blue Water Vaccines, Inc. announced that it expects to receive $8.000001 million in funding

High number of new and inexperienced directors

PDG

Titularisation

Équipe de direction

Durée moyenne de l'emploi

Âge moyen

Membres du conseil d'administration

Durée moyenne de l'emploi

Âge moyen